CDKN2A Antibody

What is CDKN2A and what cellular functions does it regulate?

CDKN2A (Cyclin-dependent kinase inhibitor 2A) is a tumor suppressor gene that encodes the protein p16INK4a, which is approximately 16.5 kilodaltons in mass . This protein acts as a negative regulator of cell proliferation by interacting strongly with CDK4 and CDK6, inhibiting their ability to bind with cyclin D and phosphorylate the retinoblastoma protein . CDKN2A is crucial for:

• Cell cycle regulation, specifically controlling G1 to S phase progression

• Induction of cellular senescence and aging

• Prevention of angiogenesis and oxidative stress

• Inhibition of metastatic processes

The protein contains 4 ANK repeats that are responsible for protein-protein interactions and is predominantly localized in both the cytoplasm and nucleus . Its expression is upregulated during cellular senescence and functions as a tumor suppressor to induce cell cycle arrest in normal tissues.

How should I select the appropriate CDKN2A antibody for my experiment?

When selecting a CDKN2A antibody, consider these experimental parameters:

For immunohistochemistry applications, several antibodies have been well-characterized, including clone JC2 (ab267833) and 2D9A12 (ab108349) . For Western blotting, antibodies like AF5779 have been validated to detect specific bands at approximately 16 kDa in human cell lines including HEK293, HepG2, and Saos-2 .

It's advisable to select antibodies that have been cited in peer-reviewed publications for your specific application to ensure reliability.

What are the optimal conditions for detecting CDKN2A by Western blot?

For optimal Western blot detection of CDKN2A:

• Sample preparation: Use RIPA or similar lysis buffer with protease inhibitors

• Protein loading: 20-30 μg of total protein per lane is typically sufficient

• Gel percentage: 12-15% SDS-PAGE gels are recommended for better resolution of the 16.5 kDa protein

• Transfer conditions: Semi-dry transfer at 15V for 30 minutes or wet transfer at 100V for 1 hour

• Blocking: 5% non-fat milk in TBST for 1 hour at room temperature

• Primary antibody: Incubate at 1:500 to 1:2,000 dilution (for most antibodies) overnight at 4°C

• Secondary antibody: HRP-conjugated at 1:5,000 to 1:10,000 for 1 hour at room temperature

Western blot data from R&D Systems using their AF5779 antibody showed detection of CDKN2A at approximately 16 kDa in human cell lines (HEK293, HepG2, and Saos-2) under reducing conditions . Some researchers have reported a secondary band at approximately 25 kDa, which may represent a post-translationally modified form of the protein .

When optimizing, it's important to note that expression levels vary significantly between cell types, with some cancer cell lines showing loss of p16INK4a expression due to deletions or methylation of the CDKN2A locus.

How can I optimize immunohistochemical detection of CDKN2A in FFPE tissues?

Optimizing IHC detection of CDKN2A in formalin-fixed, paraffin-embedded (FFPE) tissues requires:

• Antigen retrieval: Heat-induced epitope retrieval (HIER) using EDTA buffer (pH 8.0) or citrate buffer (pH 6.0) is essential. TEDTA buffer (pH 8) has shown good results with antibodies like ab267833 .

• Antibody selection: Mouse monoclonal antibodies like JC2 (ab267833) and 1D7D2A1 (ab201980) have shown good specificity for p16INK4a in FFPE tissues .

• Antibody dilution: Start with 1:50 dilution for 30 minutes at room temperature for most commercial antibodies, then optimize based on signal-to-noise ratio.

• Signal detection: DAB (3,3'-diaminobenzidine) as a chromogen typically provides good visualization.

• Positive controls: Include tissues known to express high levels of p16INK4a such as cervical high-grade squamous intraepithelial lesions (HSIL) or cervical cancer.

• Interpretation: Positive p16INK4a staining is typically nuclear and cytoplasmic. Strong, diffuse staining is often associated with HPV-related neoplasms, while focal or weak staining may be seen in non-HPV-related tissues.

For optimal results, pronase pretreatment has been successfully used with antibodies like Ab-1 (Oncogene Research Products) at 1:25 dilution for renal tumor tissue microarrays .

How can I functionally characterize CDKN2A variants of uncertain significance (VUS)?

Functional characterization of CDKN2A VUS requires specialized assays that assess the impact of the variant on protein function:

• Cell proliferation assay: This measures the ability of CDKN2A variants to inhibit cell growth when expressed in CDKN2A-null cell lines (e.g., PANC-1, MIA PaCa-2). Variants are classified as:

  • Functionally deleterious: cell proliferation values >0.81

  • Potentially functionally deleterious: values >0.66 and ≤0.81

  • Potentially functionally neutral: values >0.44 and ≤0.66

  • Functionally neutral: values <0.44

• Cell cycle analysis: EdU incorporation assay combined with flow cytometry can determine the percentage of cells in different phases of the cell cycle. Pathogenic CDKN2A variants show a lower percentage of cells in G1 phase and higher percentage in G2/M phase compared to benign variants .

• CDK4/6 binding assay: Assesses the specific molecular function of p16INK4a binding to CDK4/6, although this has lower predictive value than broader cellular function assays .

In a comprehensive study of 29 CDKN2A VUS, 37.9% were classified as functionally deleterious, 3.4% as potentially functionally deleterious, 10.3% as potentially functionally neutral, and 48.3% as functionally neutral . This approach can help reclassify VUS as likely pathogenic or likely benign based on ACMG guidelines.

What is the significance of CDKN2A alterations in immunotherapy response?

CDKN2A genomic alterations (GAs) have shown context-dependent associations with immunotherapy response:

This suggests that CDKN2A status may serve as a predictive rather than prognostic biomarker for immunotherapy response in specific cancer types, with the strongest evidence in urothelial carcinoma.

How do chromosome 9p21 deletions affect CDKN2A function in cancer progression?

Chromosome 9p21 deletions have complex effects on CDKN2A function and cancer progression:

• Co-deleted genes: 9p21 deletions can involve up to 26 genes beyond CDKN2A, including:

  • Other cell cycle regulators (CDKN2B, KLHL9)

  • Metabolic enzymes (MTAP)

  • Type I interferon gene cluster (including IFNE)

• Context-dependent effects: The impact of 9p21 loss varies by cancer type and stage:

  • In Barrett's esophagus (BE), CDKN2A loss paradoxically prevents esophageal adenocarcinoma (EAC) initiation by counterselecting subsequent TP53 alterations

  • In established EAC, 9p21 gene co-deletions predict poor patient survival

• Immune microenvironment effects:

  • IFNE loss (co-deleted with CDKN2A) reduces immune infiltration in BE but not EAC

  • In urothelial carcinoma, CDKN2A alterations are associated with reduced immune inflammatory pathways

  • In renal cell carcinoma, 9p21 loss has been associated with increased immune infiltration

• Phenotypic impact: CDKN2A loss suppresses the maintenance of squamous epithelium, contributing to a more aggressive phenotype in some cancers .

These findings demonstrate that CDKN2A and surrounding genes on 9p21 have context-dependent roles during disease evolution, with significant implications for cancer detection and patient management strategies.

Why might I observe variable molecular weights for CDKN2A in Western blots?

Researchers frequently observe variable molecular weights for CDKN2A in Western blots due to several factors:

Specific examples from published data:

• R&D Systems detected p16INK4a at approximately 16 kDa in HEK293, HepG2, and Saos-2 cells using AF5779 antibody

• Simple Western analysis showed detection at approximately 24 kDa using the same antibody at 10 μg/mL with HEK293 lysates

• Some researchers reported a secondary band at 25 kDa alongside the expected 16 kDa band when using AF5779 at 1:3000 dilution with mesenchymal stem cells

To address this variability, always run appropriate positive controls, optimize sample preparation conditions, and consider the possibility of post-translational modifications or alternative isoforms when interpreting results.

What controls should I include when working with CDKN2A antibodies?

Comprehensive controls for CDKN2A antibody experiments should include:

• Positive controls:

  • Cell lines with known CDKN2A expression: HeLa (positive), HepG2 (positive), Saos-2 (positive)

  • Tissues with established CDKN2A expression: cervical HSIL lesions, HPV-positive tumors

  • Recombinant CDKN2A protein for Western blot calibration

• Negative controls:

  • CDKN2A-null cell lines: Many pancreatic cancer cell lines (PANC-1, MIA PaCa-2) have homozygous CDKN2A deletions

  • CDKN2A knockout or knockdown cell models

  • Secondary antibody-only controls for background assessment

• Validation controls:

  • Multiple antibodies targeting different CDKN2A epitopes to confirm specificity

  • Peptide competition assay to verify binding specificity

  • CDKN2A genetic variants with known functional impacts as benchmarks

A functional validation approach used for CDKN2A variant characterization included known pathogenic variants (mean cell proliferation value 0.90, range: 0.84–1.03) and benign variants (mean cell proliferation value 0.26, range: 0.14–0.48) as benchmarks for interpreting variants of uncertain significance .

How can I distinguish between p16INK4a and other CDKN2A gene products?

The CDKN2A gene encodes multiple protein products through alternative splicing and alternative reading frames, making specific detection challenging:

• Antibody selection strategies:

  • p16INK4a-specific antibodies: Select antibodies raised against N-terminal epitopes unique to p16INK4a, such as ab189034

  • p14ARF-specific antibodies: Choose antibodies recognizing exon 1β-encoded sequences

  • p12 isoform detection: Requires antibodies targeting specific splice junctions

• Complementary techniques:

  • RT-PCR with isoform-specific primers to distinguish transcripts

  • Mass spectrometry to confirm protein identity based on peptide sequences

  • Subcellular localization analysis (p16INK4a is predominantly nucleocytoplasmic, while p14ARF is primarily nucleolar)

• Validated antibody examples:

  • p16INK4a-specific: JC2 clone (ab267833) , 1D7D2A1 clone (ab201980)

  • Dual-specific for p15INK4B/p16INK4A: C-7 clone (sc-377412) targets amino acids 96-138 at the C-terminus

Remember that experimental context matters - some antibodies perform differently across applications. For example, the 2D9A12 clone shows excellent specificity in immunohistochemistry but has different performance characteristics in flow cytometry .

How do functional assays for CDKN2A inform clinical interpretation of genetic variants?

Functional assays provide critical data for clinical interpretation of CDKN2A variants:

• Variant reclassification potential: In a study of 29 CDKN2A variants of uncertain significance (VUS), functional assays reclassified:

  • 11 variants (37.9%) as functionally deleterious

  • 1 variant (3.4%) as potentially functionally deleterious

  • 3 variants (10.3%) as potentially functionally neutral

  • 14 variants (48.3%) as functionally neutral

• ACMG/AMP guideline application: Validated functional data provides strong evidence (PS3) for pathogenicity classification, allowing reclassification of over 40% of assayed VUS as likely pathogenic .

• Correlation with cancer risk: Functionally deleterious variants showed cell cycle dysregulation with:

  • Significantly lower percentage of cells in G1 phase

  • Significantly higher percentage of cells in G2/M phase
    These patterns mirror the cell cycle profiles seen with known pathogenic variants .

• Functional domains insights: Mapping deleterious variants provides insight into critical functional domains:

  • p.Thr18Pro, p.Ala20Gly (N-terminal region)

  • p.Gln50Arg, p.His66Pro, p.Ala68Val, p.Asp74Ala (middle region)

  • p.Asp84Ala, p.Gly89Asp (ankyrin repeat domains)

  • p.Ala109Pro, p.Ala127Pro, p.Arg128Pro (C-terminal region)

This approach is particularly valuable for pancreatic ductal adenocarcinoma (PDAC) risk assessment, where germline CDKN2A variants significantly impact cancer predisposition.

What are the context-dependent roles of CDKN2A in cancer evolution?

CDKN2A exhibits fascinating context-dependent roles during cancer evolution:

These findings demonstrate that the same genetic alteration can have dramatically different effects depending on tissue context, stage of disease progression, and co-occurring genomic alterations.

How can CDKN2A antibodies be used to stratify patients for immunotherapy?

CDKN2A immunohistochemistry and associated genomic analyses have emerging potential for patient stratification in immunotherapy:

This stratification approach appears most validated in urothelial carcinoma, where CDKN2A alterations effectively identify patients with reduced likelihood of benefiting from ICI therapy, potentially guiding alternative treatment strategies.